| 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 北京昭衍新藥研究中心股份有限公司 | | 股份代號 | 06127 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度之末期現金股息 | | 公告日期 | 2025年3月28日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 不適用 | | 宣派股息 | 每 股 0.03 RMB | | 股東批准日期 | 有待公佈 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | HKD， 金額有待公佈 | | 匯率 | 有待公佈 | | 除淨日 | 有待公佈 | | 為符合獲取 ...

Financial Performance - For the fiscal year ending December 31, 2024, the company reported revenue of RMB 2,018,334, a decrease of 15.1% compared to RMB 2,376,487 for the previous year[5] - Gross profit for the same period was RMB 505,540, down 48.4% from RMB 979,393 year-on-year[5] - Net profit for the year was RMB 69,755, reflecting an 82.2% decline from RMB 391,553 in the prior year[5] - Profit attributable to equity shareholders was RMB 74,075, a decrease of 81.3% compared to RMB 396,993 in the previous year[5] - The total comprehensive income for the year was RMB 18,714, significantly lower than RMB 396,514 in the previous year[6] - Basic and diluted earnings per share were both RMB 0.10, down from RMB 0.53 in the previous year[7] - The group's reported revenue for 2024 is RMB 2,336,043 thousand, a decrease from RMB 2,523,160 thousand in 2023, representing a decline of approximately 7.4%[20] - The gross profit for the reportable segments in 2024 is RMB 501,254 thousand, significantly lower than RMB 972,625 thousand in 2023, indicating a decrease of about 48.5%[21] - Revenue from external customers in China for 2024 is RMB 1,579,381 thousand, down from RMB 1,797,730 thousand in 2023, reflecting a decline of approximately 12.2%[22] - Revenue from external customers in the United States for 2024 is RMB 415,422 thousand, a decrease from RMB 566,271 thousand in 2023, representing a decline of about 26.6%[22] Assets and Liabilities - The company's total assets attributable to equity shareholders stood at RMB 8,078,818, down 2.4% from RMB 8,279,316[5] - Total non-current assets reached RMB 4,364,954 thousand, an increase of 50.3% from RMB 2,905,192 thousand in 2023[8] - Current liabilities totaled RMB 1,110,568 thousand, a decrease of 24.4% from RMB 1,467,365 thousand in 2023[8] - Net assets decreased to RMB 8,079,188 thousand, down 2.4% from RMB 8,281,041 thousand in 2023[9] - The company's equity attributable to shareholders decreased slightly to RMB 8,078,818 thousand from RMB 8,279,316 thousand in 2023[9] Expenses - Operating profit decreased to RMB 107,046, down from RMB 513,162 in the previous year[6] - Research and development expenses were RMB 92,918, slightly down from RMB 96,854 year-on-year[6] - The service cost for the year ended December 31, 2024, was RMB 1,512.8 million, an increase of 8.3% from RMB 1,397.1 million in 2023[65] - General and administrative expenses for the year ended December 31, 2024, were RMB 315.9 million, up 6.6% from RMB 296.5 million for the year ended December 31, 2023, maintaining relative stability[71] - Sales and marketing expenses for the year ended December 31, 2024, were RMB 27.9 million, an increase of 13.3% from RMB 24.6 million for the year ended December 31, 2023, primarily due to increased customer acquisition costs[70] Cash Flow and Investments - Cash and cash equivalents as of December 31, 2024, were RMB 965.2 million, a decrease of 66.3% from RMB 2,862.9 million as of December 31, 2023, primarily due to the purchase of financial assets measured at fair value[77] - The capital-to-debt ratio as of December 31, 2024, was 14.0%, down from 17.4% as of December 31, 2023, mainly due to a decrease in contract liabilities[78] - The company has raised approximately HKD 6,373.6 million (approximately RMB 5,285.2 million) from its global offering, net of underwriting commissions and other estimated expenses[92] - A total of RMB 2,061.3 million is allocated to expand the company's network and service capabilities in China, with significant projects in Guangzhou and Chongqing[98] Research and Development - The company continues to focus on expanding its contract research organization services, including non-clinical and clinical research[10] - The company has developed and optimized various ophthalmic disease models, meeting diverse market research and development needs[40] - The company has established systematic non-clinical evaluation methods for GLP-1R, GCGR, and GIPR target drugs, improving new drug development efficiency[43] - The company has established a comprehensive platform for drug discovery and development, covering various stages from antibody discovery to drug development, with capabilities to express antibodies at 300-500 mg scale[47] - The company is actively involved in the evaluation of gene therapy products, cell therapy products, and nucleic acid drugs, expanding its service capabilities[45] Future Plans and Strategies - By 2025, the company plans to increase investment in non-clinical services, improve service quality standards, and expand production capacity to solidify its market share[84] - The company aims to enhance its non-clinical drug evaluation services and expand upstream and downstream service capabilities, including early drug discovery and clinical CRO services[83] - The company plans to recruit and train high-end talents with international backgrounds to improve cross-cultural communication and service capabilities[86] - The company aims to enhance its international registration capabilities to meet overseas reporting demands, particularly in the US and China, assisting more new drug development enterprises in their product launch plans[88] Compliance and Governance - The audit committee has reviewed the financial statements for the year ending December 31, 2024, and confirmed compliance with relevant accounting standards and regulations[119] - The company's auditor, KPMG, has agreed that the financial figures in the preliminary announcement align with the audited consolidated financial statements for the year[120] - The annual report for 2024 will include all relevant information as per listing rules and will be published on the company's and Hong Kong Stock Exchange's websites[122]

Core Viewpoint - The company has terminated its employee stock ownership plans for 2021 and 2022 and will proceed to cancel the repurchased shares related to these plans, which will not materially affect its financial status or operational results [1][6][7]. Summary by Sections 1. Approval Procedures and Disclosure - The company held its fourth board meeting on March 28, 2025, where it approved the cancellation of repurchased shares from the terminated employee stock ownership plans [1]. - The 2021 A-share employee stock ownership plan was approved by the board and authorized to be managed by the board without needing further shareholder approval for termination [2]. - The 2022 A-share employee stock ownership plan also received board approval and was similarly authorized for termination without additional shareholder meetings [3]. 2. Repurchase and Cancellation of Shares - The company initiated a share repurchase plan in September 2021, intending to buy back shares worth between RMB 4 million and RMB 8 million, and successfully repurchased 101,714 shares at prices ranging from RMB 75.5 to RMB 79.3 per share, totaling approximately RMB 7.998 million [3][4]. - As of January 10, 2023, the company held 68,500 shares in the 2022 employee stock ownership plan account, representing about 0.013% of the total share capital [5]. - The company will cancel a total of 129,114 shares, including 33,124 shares from the repurchase account and 95,900 shares from the 2022 employee stock ownership plan account [6]. 3. Impact of Share Cancellation - The cancellation of shares will not have a significant impact on the company's financial condition or operational results, and the management team will continue to fulfill its responsibilities diligently [6][7]. - The total number of shares after the cancellation will be 749,348,220, with A-shares remaining at 630,353,014, maintaining the same percentage of 84.12% [6]. 4. Approval for Share Cancellation - The board has received authorization from the shareholders to handle the cancellation of repurchased shares and related capital reduction without needing further shareholder meetings [7].

证券代码：603127 证券简称：昭衍新药 公告编号：2025-015 关于股份回购实施结果暨股份变动的公告 北京昭衍新药研究中心股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/3/29 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 万元~10,000 万元 5,000 | | 回购价格上限 | 27.94 元/股 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 实际回购股数 | 326.982 万股 | | 实际回购股数占总股本比例 | 0.4363% | | 实际回购金额 | 万元 5,299.18 | | 实际回购价格区间 | 13.20 元/股~18.15 元/股 | 一、 回购审批情况和回购方案内容 （二）截至本公告披露日，公司完成回购，已实际回购公司 A 股股份 3,269,820 股，占公 ...

委托单位：北京昭衍新药研究中心股份有限公司 审计单位：毕马威华振会计师事务所（特殊普通合伙） 关于北京昭衍新药研究中心股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 联系电话：010-67869582 关于北京昭衍新药研究中心股份有限公司 毕马威华振专字第 2501932 号 北京昭衍新药研究中心股份有限公司董事会： 我们接受委托，按照中国注册会计师审计准则审计了北京昭衍新药研究中心股份 有限公司（以下简称 "昭衍新药公司"）2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金 流量表、合并及母公司股东权益变动表以及相关财务报表附注，并于 2025 年 3 月 28 日签发了标准无保留意见的审计报告。 根据中国证券监督管理委员会、中华人民共和国公安部、国务院国有资产监督管 理委员会和中国银行保险监督管理委员会发布的《上市公司监管指引第 8 号——上市 公司资金往来、对外担保的监管要求》（证监会公告202226 号）以及上海证券交易所 发布的《上海证券交易所上市公司自律监管指南第 2 号 ...

Core Points - The company, JOINN LABORATORIES (CHINA) CO., LTD., was established on December 26, 2012, and is registered in the Beijing Economic and Technological Development Zone [2] - The company was approved by the China Securities Regulatory Commission (CSRC) to issue H shares on August 4, 2017, and subsequently listed on the Hong Kong Stock Exchange [2][3] - The registered capital of the company is RMB 749.34822 million [2][3] - The company aims to provide a new drug research and development technology platform for domestic and foreign enterprises, accelerating the industrialization of scientific and technological achievements [5] Company Structure - The company is a permanent joint-stock company, with all assets divided into equal shares, and shareholders are liable only to the extent of their subscribed shares [3] - The company has a total of 270,820,329 shares, with 63,035,301.4 million shares held by domestic investors, accounting for approximately 84.12% of the total share capital, and 11,899,520.6 million H shares held by foreign investors, accounting for approximately 15.88% [9] - The company can issue ordinary shares and, with approval, can also issue other types of shares [6][9] Share Issuance and Management - The company issues shares based on principles of openness, fairness, and justice, ensuring that each share of the same type has equal rights [6] - The company can increase its capital through various methods, including public offerings, private placements, and bonus shares [10] - The company has the right to repurchase its shares under specific circumstances, such as reducing registered capital or merging with other companies [11][12] Shareholder Rights - Shareholders have the right to receive dividends, attend and vote at shareholder meetings, supervise the company's operations, and transfer their shares [28] - The company must maintain a shareholder register that includes details of each shareholder and their respective shareholdings [22][25] - Shareholders can request the company to repurchase their shares if they disagree with resolutions made at shareholder meetings [28]

第二条 本制度所称舆情包括： 第一章 总则 第一条 为了提高北京昭衍新药研究中心股份有限公司（以下简称"公司"）应对 各类舆情的能力，建立快速反应和应急处置机制，正确把握和引导网络舆论导向， 及时、妥善处理各类舆情对公司股价、公司商业信誉及正常生产经营活动造成的 影响，切实保护投资者合法权益，根据《 上海证券交易所股票上市规则》、《 香港 联合交易所有限公司证券上市规则》等相关法律法规的和《 公司章程》的相关规 定，制定本制度。 （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较大影 响的事件信息。 第三条 舆情信息的分类： （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活动，使 公司已经或可能遭受损失，已经或可能造成公司股票及其衍生品种交易价格变动 的负面舆情。 （二）一般舆情：指除重大舆情之外的其他舆情。 第二章 舆情管理的组织体系及其工作职责 第四条 公司应对各类舆情《 （尤其是媒体质疑危机 ...

Core Viewpoint - The independent director of Beijing Zhaoyan New Drug Research Center Co., Ltd. has diligently fulfilled responsibilities in 2024, ensuring compliance with relevant laws and protecting the interests of minority shareholders [1][2]. Group 1: Independent Director's Background - The independent director, Zhang Fan, has a strong educational background with a Bachelor's degree in Management (Accounting) from Sun Yat-sen University and an MBA from Carnegie Mellon University, along with being a certified public accountant in the U.S. [1] - Zhang has extensive experience in the banking sector, having worked at China Construction Bank and served as a managing director at CCB International, focusing on capital market activities [1]. Group 2: Attendance and Participation - During the reporting period, the company held one shareholders' meeting, six board meetings, and three independent director meetings, with the independent director attending all meetings either in person or via communication [2][3]. - The independent director actively reviewed materials before meetings and communicated with management to understand key issues, contributing professional suggestions during discussions [3]. Group 3: Oversight and Communication - The independent director participated in discussions regarding internal control management and audit work with KPMG, focusing on audit scope, risk, and independence of auditors [3][4]. - Engagement with minority shareholders was prioritized, with the independent director attending the shareholders' meeting and monitoring shareholder inquiries on platforms like Shanghai Stock Exchange's e-interaction [3][4]. Group 4: Compliance and Audit - The independent director reviewed the company's 2023 annual report and internal control evaluation report, confirming compliance with regulations and accurate reflection of the company's operational and financial status [6][7]. - The appointment of KPMG as the auditing firm for 2024 was conducted following legal and procedural requirements, ensuring transparency and compliance [6][7]. Group 5: Related Transactions and Recommendations - The independent director conducted a pre-review of related transactions, confirming they were necessary for normal operations and priced fairly, adhering to principles of openness and fairness [5][6]. - No changes or waivers of commitments were reported during the period, and the independent director supported the nomination of board candidates, ensuring compliance with relevant regulations [6][8].

证券代码：603127 证券简称：昭衍新药 公告编号：2025-014 北京昭衍新药研究中心股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例：每股派发现金红利 0.03 元（含税）。 ? 本次利润分配方案以 2024 年度实施权益分派股权登记日扣除公司回 购专用账户上已回购股份后的总股本为基数，具体日期将在权益分派实施公告中 明确。 ? 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股 分配比例不变，相应调整分配总额，并将另行公告具体调整情况。 ? 本年度公司现金分红总额占 2024 年度归属于上市公司股东净利润的 一、利润分配方案内容 经毕马威华振会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，公司 2024 年度合并报表实现的归属于上市公司股东的净利润为人民币 时股权登记日扣除公司回购专用账户上已回购股份后的总股本为基数分配利润， 本次利润分配方案如下： 上市公司拟向全体股东每 10 股派发现金红利 0.3 元（含税）。以本公告日 公司总股 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2025-009 北京昭衍新药研究中心股份有限公司 第四届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京昭衍新药研究中心股份有限公司（以下简称"公司"或"昭衍新药"）第四 届董事会第十三次会议于 2025 年 3 月 14 日以书面送达、电子邮件等方式发出会 议通知，并于 2025 年 3 月 28 日以现场会议的形式召开。本次会议应参加董事 9 人，实际参加董事 9 人，会议由董事长冯宇霞女士主持；公司全体监事和高级管 理人员列席会议。会议的召集和召开及表决符合《中华人民共和国公司法》和《北 京昭衍新药研究中心股份有限公司章程》（以下简称"《公司章程》"）的规定， 会议程序合法、有效。 本次会议经与会董事认真审议，以举手表决方式作出了如下决议： 表决结果：董事会以 9 票赞成、0 票反对、0 票弃权的表决结果通过该议案， 同意将该议案提交 2024 年度股东大会审议。 上述议案已经公司董事会审计委员会审议通过，同意相关内容并同意提交公 司 ...